FOXO4-DRI vs Taurine
A side-by-side research comparison of FOXO4-DRI and Taurine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FOXO4-DRI | Taurine |
|---|---|---|
| Full name | FOXO4-D-Retro-Inverso Peptide (Senolytic) | Taurine (2-Aminoethanesulfonic Acid) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | OTC supplement |
| Mechanism | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. | Acts as a cytoprotective osmolyte and antioxidant, stabilizes mitochondrial function, modulates calcium signaling and GABA-A/glycine receptors, reduces inflammation, and supports bile acid conjugation. Taurine deficiency accelerates cellular senescence markers. |
| Molecular weight | ~4,500 Da | 125.15 Da |
| Half-life | 12-24 hours (D-amino acid stability) | ~1 hour (plasma) |
| Bioavailability | Moderate (SubQ) | ~90-100% oral |
| Typical dose | 5-10 mg/kg (animal studies) | 1-6 g per day |
| Frequency | 3x per week for 3 weeks | 1-3x daily |
| Route | Subcutaneous | Oral (powder or capsule) |
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
Taurine reported benefits
- Supports mitochondrial function
- Cardiovascular and blood pressure support
- Exercise endurance
- Antioxidant and anti-inflammatory
- Longevity/healthspan signal
- Calming/GABAergic effects
Related comparisons
Research and educational reference only. Not medical advice.